



**World Health
Organization**

INN Working Document 20.484
13/07/2020

**Addendum¹ to
"The use of stems in the selection of International
Nonproprietary names (INN) for pharmaceutical
substances" WHO/EMP/RHT/TSN/2018.1**

Programme on International Nonproprietary Names (INN)

Medicines and Health Products

World Health Organization, Geneva

© World Health Organization 2020 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme.

This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Addendum¹ to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/RHT/TSN/2018.1

¹ This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of *"The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances"* 2018.

-adenant adenosine receptors antagonists

ciforadenant (118), preladenant (99), taminadenant (120), tozadenant (106), vipadenant (103)

-caftor cystic fibrosis transmembrane regulator (CFTR) protein modulators, correctors, and amplifiers

bamocaftor (121), deutivacaftor (118), elexacaftor (121), galicaftor (119), icenticaftor (122), ivacaftor (104), lumacaftor (105), navocaftor (121), nesolicaftor (122), olacaftor (119), posenacaftor (122), tezacaftor (114)

-calcet/-calcet- calcium-sensing receptors (CaSR) agonists

cinacalcet (88), etelcalcetide (112), evocalcet (113), tecalcet (87), upacalcet (118)

-cerfont corticotropin-releasing factor (CRF) receptor antagonists

crinecerfont (120), emicerfont (102), pexacerfont (97), tildacerfont (119), verucerfont (102)

-copan complement receptor antagonists/ complement inhibitors

avacopan (114), danicopan (119), iptacopan (122), nomacopan (119)

(c) category: pegcetacoplan (120), zilucoplan (118)

-corat glucocorticoid receptor agonists

dagrocorat (111), fosdagrocorat (111), mapracorat (102), tomicorat (108), velsecorat (121)

-fexor

farnesoid X receptor agonists

cilofexor (119), nidufexor (118), tropifexor (116), turofexorate isopropyl (103), vonafexor (122)

-fusp

fusion proteins¹

bintrafusp alfa (121), cinrebafusp alfa (121), clervonafusp alfa (120), lorukafusp alfa (120), modakafusp alfa (122), onfekafusp alfa (118), pabinafusp alfa (120), rozibafusp alfa (120), simlukafusp alfa (121), tagraxofusp (118), tebentafusp (118), valanafusp alfa (118)

-golix

gonadotropin releasing hormone (GnRH) antagonists

elagolix (99), linzagolix (118), opigolix (118), relugolix (107), sufugolix (89)

-ixafor

chemokine CXCR4 antagonists

balixafortide (112), burixafor (104), mavorixafor (118), motixafortide (120), plerixafor (93)

-ixibat

ileal bile acid transporter (IBAT) inhibitors, bile acid reabsorption inhibitors

barixibat (88), elobixibat (104), linerixibat (118), maralixibat chloride (113), odevixibat (119), volixibat (113)

-leuton

5-lipo-oxygenase inhibitors, anti-inflammatory

atreleuton (78), diroleuton (118), epeleuton (118), fenleuton (72), setileuton (101), zileuton (63)

¹ A fusion protein is defined as a multifunctional protein derived from a single nucleotide sequence which may contain two or more genes or portions of genes with or without amino acid linker sequences. The genes should originally code for separate proteins, with at least two of them endowed with pharmacological action (e.g. action and targeting). "Notes from the fusion protein Working Group", INN Working Document number 17.414 rev.

stat

enzyme inhibitors

-becestat

beta secretase inhibitors

atabecestat (117), elenbecestat (117), umibecestat (119), lanabecestat (116), verubecestat (112)

-glustat

ceramide glucosyltransferase inhibitors

duvoglustat (102), eliglustat (103), miglustat (85), sinbaglustat (121), venglustat (114)

-tinib

tyrosine kinase inhibitors

-ertinib

epidermal growth factor receptor (EGFR) inhibitors

abivertinib (119), osimertinib (113), epertinib (115), canertinib (87), lazertinib (117), mavelertinib (118), mobocertinib (121), olafertinib (121), rezivertinib (122), xiliertinib (121), zorifertinib (121)

(b) category: ulixertinib (113), ravoxertinib (115) (Erk inhibitors)

(c) category: afatinib (104), olmutinib (114), erlotinib (85), gefitinib (85), mubritinib (90), nazartinib (114), mubritinib (90), nazartinib (114)

-tirom(-)

antihyperlidaemic; thyromimetic derivatives

acetiromate (30), axitirome (82), bentiromide (41), eprotirome (99), resmetirom (119), sobetirome (100)

-toclax

B-cell lymphoma 2 (Bcl-2) inhibitors, antineoplastics

obatoclax (94), navitoclax (103), venetoclax (111), imlatoclax (115), pelcitoclax (122), tanotoclax (121), mirzotamab clezotoclax (121), murizatoclax (122)

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24492

